The earliest clinical use of growth hormone therapy dates to the mid-20th century, when researchers extracted the hormone from the pituitary glands of human cadavers to treat children with growth hormone deficiency. This approach established the basic clinical rationale for GH replacement, but it was fundamentally supply-constrained — each dose required pooling material from multiple donors.
Beyond scarcity, cadaveric extraction carried a serious documented risk: cases were linked to transmission of Creutzfeldt-Jakob disease, a rare and severe neurological condition, through contaminated pituitary material. This safety concern ultimately led to the discontinuation of cadaveric-derived HGH in the 1980s.
Recombinant DNA technology offered a way out of both problems at once. Scientists inserted the gene encoding human growth hormone into a host organism, historically bacteria, engineering it to manufacture the hormone as it grew inside controlled bioreactors. The resulting protein was purified into pharmaceutical-grade somatropin.
This approach eliminated the disease-transmission risk entirely, since it required no human donor material, and it allowed production at a scale cadaveric extraction could never approach. The first recombinant somatropin products received regulatory approval in the 1980s, opening growth hormone therapy to a far broader patient population than the extraction era ever could.
In the decades since recombinant approval, multiple pharmaceutical manufacturers have developed their own somatropin formulations, delivery devices, and manufacturing processes, each independently demonstrating safety and efficacy to regulators. Delivery technology has evolved substantially over this period, from reconstituted vials toward pre-filled pen and cartridge systems.
Post-marketing surveillance and long-term outcome studies have continued to refine understanding of the therapy's safety profile across this extended period of use, contributing to one of the more thoroughly documented clinical research histories among biologic hormones.
Understanding this history explains why recombinant somatropin, despite being manufactured rather than extracted, is described in pharmacology literature as structurally identical to the naturally occurring hormone — the recombinant process was designed specifically to reproduce it faithfully, not to create a novel variant.
This is manufacturing and regulatory history published for research-education purposes only. REVIVE LAB UAE does not manufacture, sell, or handle HGH in any form, and this article makes no product or purchase claim.